Tyra Biosciences, Inc. SEC Filings

Tyra Biosciences, Inc. (TYRA)11/21/2025, the fund sold 246,871 shares of common stock in an open-market transaction coded as a sale. The shares were sold under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2025.

The filing states a weighted average sale price of $20.2536 per share, with individual sale prices ranging from $20.25 to $21.24. After this transaction, 3,833,425 shares of Tyra Biosciences common stock are reported as beneficially owned indirectly through the fund. The reporting person notes that beneficial ownership is disclaimed beyond his pecuniary interest in those shares.

Tyra Biosciences, Inc. reported insider stock sales by its Chief Operating Officer. The executive filed a Form 4 showing open-market sales of Tyra common stock on 11/18/2025 and 11/19/2025. On the first date, the officer sold 75,633 shares of common stock at a weighted average price of $16.0727, leaving 220,937 shares beneficially owned directly afterward. On the second date, the officer sold an additional 49,956 shares at a weighted average price of $16.3203, and reported direct beneficial ownership of 170,981 shares following that transaction. The filing notes that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024, which is designed to allow insiders to sell shares according to a preset schedule.

Tyra Biosciences, Inc. Chief Operating Officer, listed as an officer and sole reporting person, reported multiple open-market sales of common stock. On 11/13/2025, the COO sold 1,111 shares at a weighted average price of $16.0036, leaving 426,870 shares beneficially owned. On 11/14/2025, an additional 110,228 shares were sold at a weighted average price of $16.0167, reducing beneficial ownership to 316,642 shares. On 11/17/2025, the COO reported sales of 18,572 shares at a weighted average price of $16.1098 and 1,500 shares at a weighted average price of $17.0713, resulting in 296,570 shares of common stock beneficially owned following the transactions.

The filing states that all reported sales were effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024, and that the disclosed prices represent weighted averages over multiple trades within specified price ranges.

Tyra Biosciences (TYRA) reported a wider quarterly net loss as it advanced multiple clinical programs. For the three months ended September 30, 2025, the company posted a net loss of $29.9 million versus $24.0 million a year ago. Operating expenses rose to $32.9 million, driven by R&D of $25.5 million and G&A of $7.5 million, while interest and other income contributed $3.1 million.

Liquidity remains strong with cash, cash equivalents and marketable securities of $274.9 million as of September 30, 2025. Net cash used in operations was $71.5 million for the first nine months of 2025. Management states this cash position is expected to fund operations through at least 2027.

Development highlights include progress across FGFR programs: dabogratinib Phase 2 studies in pediatric achondroplasia (BEACH301) and NMIBC (SURF302) are underway, UTUC (SURF303) received FDA clearance to initiate Phase 2, and TYRA-430 began dosing in a global Phase 1. Shares outstanding were 53,318,198 as of September 30, 2025; 53,372,098 were outstanding as of October 31, 2025.

Tyra Biosciences, Inc. filed an 8-K announcing it issued a press release covering financial results for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.

Consistent with General Instruction B.2, the information in this report, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. The filing lists the company’s common stock under the symbol TYRA on the Nasdaq Global Select Market.

Tyra Biosciences insider purchase under ESPP: The company's Chief Financial Officer, Alan Fuhrman, acquired 701 shares of Tyra Biosciences common stock on 09/15/2025 at a purchase price of $9.129 per share under the issuer's 2021 Employee Stock Purchase Plan. After the transaction, Mr. Fuhrman beneficially owned 14,788 shares. The Form 4 was signed by an attorney-in-fact on 09/17/2025.

Tyra Biosciences (TYRA) reported items from its Quarterly Report that describe capital structure, recent equity transactions, stock plan availability, cost drivers and development risks. The company had 53,233,494 shares issued and outstanding at June 30, 2025, compared with 50,754,262 issued and 50,749,945 outstanding at December 31, 2024. A 2022 Sales Agreement was terminated in May 2025 and no shares were sold under it; no shares had been sold under a 2025 Sales Agreement as of June 30, 2025. RA Capital exchanged 1,000,000 shares for pre-funded warrants exercisable at $0.001 per share; the Exchange closed October 22, 2024, and the warrants are classified in stockholders' equity. As of June 30, 2025, 5,189,786 shares were available for future grant under the 2021 Plan and 1,972,762 shares remained available for purchase under the ESPP, which offers a purchase price at 85% of the lower of two dates. The company disclosed increases in costs: $4.1 million and $9.6 million driven by clinical start-up and CMC activities, and increases of $2.4 million and $4.5 million in compensation and personnel expenses (including $1.0 million and $2.2 million higher stock-based compensation), partially offset by $0.2 million lower facilities costs. The filing lists numerous development, regulatory, operational and geopolitical risks that could affect timelines, costs and commercialization prospects.

Janus Henderson Group plc reported beneficial ownership of 2,856,290 shares of Tyra Biosciences common stock, equal to 5.4% of the class, in a Schedule 13G/A filing. The statement shows 0 shares of sole voting or dispositive power and 2,856,290 shares of shared voting and shared dispositive power, indicating the reported interest is held collectively by related entities. The filing identifies the reporting person type as IA, HC and lists indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) as registered investment advisers furnishing advice to Managed Portfolios. A power of attorney authorizes named employees to prepare and file U.S. reporting forms on the group's behalf.